BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1832885)

  • 1. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
    Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
    Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1217-22. PubMed ID: 1292506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2.
    Lissoni P; Pittalis S; Brivio F; Tisi E; Rovelli F; Ardizzoia A; Barni S; Tancini G; Giudici G; Biondi A
    Cancer; 1993 Mar; 71(6):2076-81. PubMed ID: 8443757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo biological results of the association between interleukin-2 and interleukin-3 in the immunotherapy of cancer.
    Lissoni P; Barni S; Tisi E; Rovelli F; Pittalis S; Rescaldani R; Vigoré L; Biondi A; Ardizzoia A; Tancini G
    Eur J Cancer; 1993; 29A(8):1127-32. PubMed ID: 8390845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
    Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
    J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
    Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
    J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical value of soluble interleukin-2 receptor in infectious complications.
    Iwagaki H; Hizuta A; Iwadou H; Perdomo JA; Tanaka N; Orita K
    Acta Med Okayama; 1994 Aug; 48(4):225-6. PubMed ID: 7817778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
    Ott M; Demisch L; Engelhardt W; Fischer PA
    J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
    Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
    J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
    Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
    Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
    Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
    J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neopterin serum levels in pancreatic adenocarcinoma.
    Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
    Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
    Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
    J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis.
    Samsonov MY; Nassonov EL; Tilz GP; Geht BM; Demel U; Gurkina GT; Shtutman VZ; Guseva AG; Wachter H; Fuchs D
    Br J Rheumatol; 1997 Jun; 36(6):656-60. PubMed ID: 9236675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 is a survival prognostic factor in renal cell carcinoma.
    Thiounn N; Pages F; Flam T; Tartour E; Mosseri V; Zerbib M; Beuzeboc P; Deneux L; Fridman WH; Debré B
    Immunol Lett; 1997 Jul; 58(2):121-4. PubMed ID: 9271323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.